FI964920A0 - Novel farnesyltransferase inhibitors, their preparation and pharmaceutical preparations containing them - Google Patents
Novel farnesyltransferase inhibitors, their preparation and pharmaceutical preparations containing themInfo
- Publication number
- FI964920A0 FI964920A0 FI964920A FI964920A FI964920A0 FI 964920 A0 FI964920 A0 FI 964920A0 FI 964920 A FI964920 A FI 964920A FI 964920 A FI964920 A FI 964920A FI 964920 A0 FI964920 A0 FI 964920A0
- Authority
- FI
- Finland
- Prior art keywords
- radical
- alkyl
- optionally substituted
- general formula
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Novel farnesyl transferase inhibitors of general formula (I), their preparation and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1 -(Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or an R4-S radical in which R4 is an alkyl radical containing 1-4 carbon atoms optionally substituted by a phenyl radical or a radical of general formula (II), in which A1, X1, Y1, R'1, R2, R'2 and R are defined as follows: A1 is an alkylene radical containing 1-4 carbon atoms optionally a substituted at alpha in the grouping >C(X1)(Y1) with an amino or alkylamino, dialkylamino, alkanylamino or alkoxycarbonylamino radical), X1 and Y1 are each a hydrogen atom or form together with the carbon atom to which they are connected a >C=O grouping, R'1 is hydrogène or methyl, R2 is an alkyl, alkenyl or alkynyl radical containing 1-6 carbon atoms optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulfinyl or alkylsulfonyl, with the proviso that when R2 is an alkyl radical substituted by a hydroxy radical, R2 can form a lactone with the carboxy radical at alpha . R'2 is hydrogen or methyl and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical, whith the proviso that the radical (a) is in position 5 or 6 of the naphthyl ring. These novel products have anti-cancer properties.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9407116A FR2721021B1 (en) | 1994-06-10 | 1994-06-10 | New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions containing them. |
FR9412338A FR2725717B1 (en) | 1994-10-17 | 1994-10-17 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PCT/FR1995/000739 WO1995034535A1 (en) | 1994-06-10 | 1995-06-07 | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
FI964920A0 true FI964920A0 (en) | 1996-12-09 |
FI964920A FI964920A (en) | 1996-12-09 |
Family
ID=26231226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964920A FI964920A (en) | 1994-06-10 | 1996-12-09 | New farnesyl transferase inhibitors, their preparation and those containing pharmaceutical preparations |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0764149B1 (en) |
JP (1) | JPH10501259A (en) |
CN (1) | CN1150419A (en) |
AT (1) | ATE175958T1 (en) |
AU (1) | AU2742195A (en) |
BR (1) | BR9508187A (en) |
CA (1) | CA2192389A1 (en) |
CZ (1) | CZ361996A3 (en) |
DE (1) | DE69507476D1 (en) |
FI (1) | FI964920A (en) |
NO (1) | NO965160L (en) |
PL (1) | PL317580A1 (en) |
SK (1) | SK158196A3 (en) |
TW (1) | TW365602B (en) |
WO (1) | WO1995034535A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998038162A1 (en) * | 1997-02-27 | 1998-09-03 | Eisai Co., Ltd. | Inhibitors of isoprenyl transferase |
GB2323842A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv | Pyridine derivatives |
GB2323841A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv Group Holdings | Pyridine derivatives with anti-tumor and anti-inflammatory activity |
US6071547A (en) * | 1998-10-08 | 2000-06-06 | Superior Nutrition Corporation | Textured dry mix instant nutritional drink |
US6486202B1 (en) | 2001-04-13 | 2002-11-26 | Eisai Company, Limited | Inhibitors of isoprenyl transferase |
EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
MX2008013427A (en) | 2006-04-19 | 2008-11-04 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling. |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009007200A (en) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors. |
EP2132177B1 (en) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
EP2152700B1 (en) | 2007-05-21 | 2013-12-11 | Novartis AG | Csf-1r inhibitors, compositions, and methods of use |
AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP6073677B2 (en) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Fused heterocyclic compounds and their use |
EA023838B1 (en) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2791613A1 (en) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
JP6280554B2 (en) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
ME02925B (en) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Compositions and methods for treating cancer |
TW201429969A (en) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | Substituted imidazopyridines as HDM2 inhibitors |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
JP6491202B2 (en) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7) |
ES2676734T3 (en) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Heteroatomic compounds useful for the treatment of proliferative diseases |
CN105849087A (en) | 2013-12-27 | 2016-08-10 | 诺华丝国际股份有限公司 | Ethoxylated surfactants |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017162122A1 (en) * | 2016-03-23 | 2017-09-28 | Yu-Jen Chen | Farnesyl transferase inhibitors and uses thereof |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
EP3609922A2 (en) | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2044333A1 (en) * | 1990-06-12 | 1991-12-13 | Jackson B. Gibbs | Chemotherapeutic agents |
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5504212A (en) * | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-06-07 CA CA002192389A patent/CA2192389A1/en not_active Abandoned
- 1995-06-07 AU AU27421/95A patent/AU2742195A/en not_active Abandoned
- 1995-06-07 SK SK1581-96A patent/SK158196A3/en unknown
- 1995-06-07 EP EP95922573A patent/EP0764149B1/en not_active Expired - Lifetime
- 1995-06-07 BR BR9508187A patent/BR9508187A/en not_active Application Discontinuation
- 1995-06-07 TW TW084105739A patent/TW365602B/en active
- 1995-06-07 AT AT95922573T patent/ATE175958T1/en not_active IP Right Cessation
- 1995-06-07 WO PCT/FR1995/000739 patent/WO1995034535A1/en not_active Application Discontinuation
- 1995-06-07 DE DE69507476T patent/DE69507476D1/en not_active Expired - Lifetime
- 1995-06-07 CN CN95193511A patent/CN1150419A/en active Pending
- 1995-06-07 CZ CZ963619A patent/CZ361996A3/en unknown
- 1995-06-07 PL PL95317580A patent/PL317580A1/en unknown
- 1995-06-07 JP JP8501714A patent/JPH10501259A/en active Pending
-
1996
- 1996-12-03 NO NO965160A patent/NO965160L/en unknown
- 1996-12-09 FI FI964920A patent/FI964920A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ361996A3 (en) | 1997-04-16 |
EP0764149B1 (en) | 1999-01-20 |
WO1995034535A1 (en) | 1995-12-21 |
DE69507476D1 (en) | 1999-03-04 |
ATE175958T1 (en) | 1999-02-15 |
CA2192389A1 (en) | 1995-12-21 |
BR9508187A (en) | 1997-08-12 |
EP0764149A1 (en) | 1997-03-26 |
FI964920A (en) | 1996-12-09 |
TW365602B (en) | 1999-08-01 |
CN1150419A (en) | 1997-05-21 |
SK158196A3 (en) | 1997-07-09 |
JPH10501259A (en) | 1998-02-03 |
PL317580A1 (en) | 1997-04-14 |
NO965160D0 (en) | 1996-12-03 |
AU2742195A (en) | 1996-01-05 |
NO965160L (en) | 1996-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI964920A0 (en) | Novel farnesyltransferase inhibitors, their preparation and pharmaceutical preparations containing them | |
FI972366A (en) | Lipopolyamines as transfecting agents and their pharmaceutical use | |
DE69628559D1 (en) | Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase | |
CA2304713A1 (en) | Biphenyl-5-alkanoic acid derivatives and use thereof | |
NO973222L (en) | New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the inhibitors | |
DE69415445T2 (en) | Cytotoxic stilbene derivatives and pharmaceutical compositions containing them | |
WO2004071388A3 (en) | Medicinal compounds | |
DE69230958T2 (en) | Medicinal composition based on dioxabicyclo [3.3.0] octane derivatives | |
ES8200011A1 (en) | Pharmaceutical composition containing a diphenylhydantoin derivative, derivatives used and their preparation. | |
GR3001879T3 (en) | Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them | |
MXPA03000547A (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. | |
ES8205791A1 (en) | 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them. | |
MX9301345A (en) | PROCEDURE FOR THE PREPARATION OF TAXANE DERIVATIVES. | |
IL95762A0 (en) | Benzanilides,their preparation and pharmaceutical compositions containing the same | |
MX9606106A (en) | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same. | |
FI932641A0 (en) | Now estradiol derivative-chlorambucil-conjugate, for the preparation of pharmaceuticals and pharmaceutical compositions | |
CY1106058T1 (en) | STABLE COMPOSITIONS OF OXAPENEM-3-CARBOXYLIC ACIDS CO-LYOPHILOZING WITH PHARMACEUTICAL CARRIERS | |
DE60119383D1 (en) | FARNESYL TRANSFERASE-INHIBITING 4-HETEROCYCLYLCHINOLIN AND CHINAZOLINE DERIVATIVES | |
AU579665B2 (en) | 2-pyridine-thiol derivatives | |
SE9701912D0 (en) | Pharmaceutical composition and use thereof | |
KR950702566A (en) | Diphosphonic Acid Derivatives Containing Chain Amidine Groups, Methods for Making the Same, and Pharmaceutical Compositions Comprising the Same | |
ES2023760A6 (en) | Benzothiazine derivatives, their preparation and their uses as medicines or as intermediates for the synthesis of medicines. | |
MX9706015A (en) | Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same. | |
MX9705969A (en) | Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same. | |
MX9802679A (en) | Dithiolan derivatives, their preparation and their therapeutic effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |